Comprehensive profiling of axiogenesis ventricular vCor.4U iPSC-derived cardiomyocytes—From electrophysiology to phenotypic assays

MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

“…Pharmacological inhibition by F1386-0303 was highly protective, suppressing human cardiac muscle cell death in iCell cardiomyocytes even at micromolar concentrations (DRAQ7 uptake; Figure S5A), equaling the benefit achieved by gene silencing. Human cardiac muscle cell protection was substantiated in a second line, vCor.4U cardiomyocytes, which was likewise validated as physiologically predictive (Blinova et al., 2018, El-Haou et al., 2018) but is more highly enriched for ventricular myocytes—the clinically relevant subtype. The ventricle-specific protein MLC 2V was readily detected in >80% of vCor.4U cardiomyocytes (Figure S5B) but just a minority of iCell cardiomyocytes (Kattman et al., 2011).…”